China SXT Pharmaceuticals Inc (SXTC) — Working Capital to Net Assets Ratio
China SXT Pharmaceuticals Inc (SXTC) has a Working Capital to Net Assets ratio of 101.5% as of June 2026. Working capital of $30.16 Million (current assets of $34.51 Million minus current liabilities of $4.35 Million) is measured against net assets of $29.71 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See SXTC free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
China SXT Pharmaceuticals Inc Working Capital to Net Assets (2016–2026)
This chart shows how China SXT Pharmaceuticals Inc's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2016 to 2026. As of June 2026, the ratio stands at 101.5%, reflecting working capital of $30.16 Million against net assets of $29.71 Million USD. See China SXT Pharmaceuticals Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for China SXT Pharmaceuticals Inc (2016–2026)
The table below presents the year-by-year Working Capital to Net Assets ratio for China SXT Pharmaceuticals Inc from 2016 to 2026, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see China SXT Pharmaceuticals Inc market capitalisation.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2026 | 101.5% | $30.16 Million | $29.71 Million | $34.51 Million | $4.35 Million | ▲ +2.5 pp |
| 2025 | 99.0% | $15.28 Million | $15.44 Million | $21.30 Million | $6.01 Million | ▲ +60.7 pp |
| 2024 | 38.3% | $5.33 Million | $13.93 Million | $14.23 Million | $8.90 Million | ▲ +4.1 pp |
| 2023 | 34.2% | $5.02 Million | $14.69 Million | $19.52 Million | $14.50 Million | ▲ +1.7 pp |
| 2022 | 32.5% | $5.33 Million | $16.42 Million | $22.45 Million | $17.12 Million | ▲ +3.3 pp |
| 2021 | 29.2% | $4.65 Million | $15.96 Million | $23.23 Million | $18.58 Million | ▼ -49.3 pp |
| 2020 | 78.4% | $7.37 Million | $9.40 Million | $19.64 Million | $12.26 Million | ▼ -5.0 pp |
| 2019 | 83.4% | $9.27 Million | $11.11 Million | $15.59 Million | $6.32 Million | ▲ +30.8 pp |
| 2018 | 52.7% | $1.73 Million | $3.29 Million | $6.10 Million | $4.37 Million | ▼ -18.9 pp |
| 2017 | 71.6% | $1.33 Million | $1.85 Million | $4.91 Million | $3.58 Million | ▲ +47.3 pp |
| 2016 | 24.3% | $180.22K | $742.77K | $5.73 Million | $5.55 Million | — |